

Miscellaneous Tariff Bill

Final Disclosure Form

Part I: Type of Disclosure

This form is being submitted for H.R. 5698 as a disclosure submitted reflecting information provided through MTB public comment period and the International Trade Commission's Congressional Bill Report.

Part II: Written Statement

Member Name: Erik Paulsen

- A. Is the tariff relief specified in this Miscellaneous Tariff Bill available to any entity that imports and pays duties pursuant to this tariff heading? If not, why?

Yes

Please list any known entities currently importing under the tariff heading specified in the Miscellaneous Tariff Bill, including those listed in the Preliminary Disclosure Form, ITC Congressional Bill Report, and any public comments: (if additional space is required, please attach with this form)


Teva Pharmaceuticals USA

- B. Does the tariff relief specified in this Miscellaneous Tariff Bill benefit downstream producers, manufacturers, purchasers, and consumers?

YES

Part III: Financial Benefit Certification

I hereby certify that neither myself nor my spouse has a financial interest in any entity named in Part II.A above.



(Member Signature)

11/27/2012

Date



TEVA PHARMACEUTICALS

June 22, 2012

Representative Dave Camp
Chairman
Committee on Ways and Means
1102 Longworth Office Building
Washington, DC 20515

Representative Sander M. Levin
Ranking Member
Committee on Ways and Means
1106 Longworth Office Building
Washington, DC 20515

Dear Chairman Camp and Ranking Member Levin:

I am writing in support of H.R. 5698, legislation temporarily suspending the duty on S-(2-benzothiazolyl)-2-(2-amino-thiazol-4-yl)-2-acetoxyimino thioacetate (Thioester).

Thioester is a raw material used by Teva Pharmaceuticals in the production of the active pharmaceutical ingredient, Cefdinir, a cephalosporin antibiotic. This finished product is used to treat certain kinds of bacterial infections.

Because Teva is unaware of any domestic manufacturers of Thioester, the company must rely on suppliers outside of the United States. Currently, Teva imports this material from a company in India but in the future could have to source the material from China in order to meet our supply needs.

Through 2015, Teva anticipates paying over \$200,000 in duties from having to import this material. A temporary suspension of this duty will allow Teva to continue to provide low cost medications to consumers and purchasers and compete in the global marketplace.

Thank you for providing the opportunity to voice our support for this legislation and we urge its inclusion in any final Miscellaneous Trade Bill.

Sincerely,

Heather M. Connor-Garofalo
Director, Customs Compliance
Teva Pharmaceuticals USA, Inc.